SOURCE: NanoLogix

March 13, 2007 11:52 ET

NanoLogix Files a Provisional Patent Application for Treatment of Leukemia

SHARON, PA -- (MARKET WIRE) -- March 13, 2007 -- NanoLogix, Inc. (PINKSHEETS: NNLX) announced today that it has filed a provisional patent application with the U.S. Patent Office entitled "A Hydrophobic Hydrocarbon Coated Filtering Device for the Induction of Apoptosis in Leukemic Cells and Related Methods of Treating a Patient." This intellectual property application was filed by the Pittsburgh law firm of Eckert, Seamans, Cherin and Mellott, LLC. The invention describes a number of unique and innovative methods for killing leukemia cells outside of a patient's body by dialyzing, irradiating and biothermically manipulating the cancer cells, thereby killing the leukemia cells extracorporeally in a relatively nontoxic manner.

Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix, Inc., stated, "I believe that this is a truly exciting and previously unexplored therapeutic avenue for attacking leukemia, and related cancers. It is our intention to greatly accelerate the development of this promising methodology by partnering with a major university and pharmaceutical firm in the oncology arena."

About NanoLogix, Inc.:

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the nontoxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information